Health
Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward – TCTMD
DREAM-HF provides hints of an anti-inflammatory effect and benefits beyond the heart, setting up future trials.
Targeted injection of mesenchymal precursor cells (MPCs) into the myocardium is safe but does not reduce recurrent nonfatal decompensated heart failure (HF) events in patients with chronic HF with reduced ejection fraction (HFrEF), the randomized DREAM-HF…
Continue Reading
-
Noosa News19 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
Business22 hours agoWhy you should sell CBA, Lynas, and Tabcorp shares today
-
General12 hours agoAustralia Kangaroos lose Xavier Coates and Zac Lomax ahead of rugby league Ashes in England
-
Business21 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400